venetoclax + chidamide + azacitidine

Venetoclax + chidamide + azacitidine is a combination therapy under investigation for the treatment of acute myeloid leukemia (AML) and relapsed/refractory B-cell acute lymphoblastic leukemia. Venetoclax is a potent, selective oral inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), which promotes apoptosis in malignant cells. Chidamide is an oral histone deacetylase inhibitor that modulates epigenetic regulation and can overcome resistance mechanisms such as MCL-1 upregulation induced by venetoclax. Azacitidine is a DNA methyltransferase inhibitor (a hypomethylating agent) that reactivates silenced genes through demethylation, contributing to anti-leukemic effects. The combination has shown synergistic activity in preclinical models and early-phase clinical trials, with high response rates and manageable safety profiles in elderly patients with newly diagnosed AML or relapsed/refractory disease[1][4][5][6]. This regimen works by promoting apoptosis via inhibition of BCL-2, altering gene expression through histone deacetylase inhibition, and reversing aberrant DNA methylation.

Other names

ABC regimenCACAG-VEN regimen